Following promising ASCO readout for AMG 510, Amgen looks to identify more KRAS-mutant patients

By Allison Johnson, Staff Writer | Jun 3, 2019 | 10:04 PM GMT

After making a strong showing at ASCO with data for its KRAS inhibitor in non-small cell lung cancer patients, Amgen will now look to expand the program's options for finding trial-eligible patients.

Amgen Inc. (NASDAQ:AMGN) reported updated Phase I

Read the full 389 word article

How to gain access

Continue reading with a
two-week free trial.